SAGA Diagnostics

We deliver cancer diagnostics insights that provide doctors with precision treatment strategies that can provide better care to patients. We believe: Better diagnostics lead to better outcomes.

At Sagis Diagnostics, we are committed to teaching the art and science of diagnostic pathology. With board-certified and subspecialty-trained pathologists always within reach, we deliver the highest quality services to physicians, physician groups, ambulatory surgery centers, and hospitals. Our commitment to quality and excellence is built upon our expertise and the utilization of the latest diagnostic tools. As a patient-centric facility, we strive to deliver the best medical care possible. Sagis remains at the forefront of diagnostic science to quickly deliver accurate results backed by unmatched personal service. With accurate patient testing as our top priority, Sagis Toxicology applies leading technological advancements and methods that follow the strictest guidelines overseen by CLIA and CAP accreditation. Our molecular assays deliver crucial diagnostic, therapeutic, and prognostic information to physicians and patients. Along with focusing on your diagnosis, Sagis’ elite team of diagnostic pathologists also remains trusted by industry leaders.

We are specialists in finding these molecular alterations & in developing diagnostic technology, among others Liquid Biopsy. PANGAEA Oncology is a company focused on Precision Oncology, which offers both patients and pharmaceutical companies different services with the aim of improving the survival of cancer patients, their response to treatments, and their quality of life. The company has two main areas of activity interrelated, such as the clinical care division and the state-of-the-art laboratory that provides services in various areas, including molecular diagnostics as a reference laboratory for both patients and industry, pre-treatment services (clinic to industry), and diagnostic consultancy. PANGAEA ONCOLOGY’s mission is to change the natural history of the disease, improving the survival of cancer patients, through the application of the best professionals and technologies. To position PANGAEA ONCOLOGY as the reference in Europe in Precision Oncology, from patient treatment, the provision of services to the industry, the incorporation of disruptive technology and medical-scientific excellence, and directed towards systems intelligent IT and data exploitation (IA/BIG DATA). PANGAEA ONCOLOGY is a company focused on Precision Oncology, which offers both patients and pharmaceutical companies different services with the aim of improving the survival of cancer patients, their response to treatments, and their quality of life. Position PANGAEA ONCOLOGY as the reference in Southern Europe in Precision Oncology, from patient treatment, the provision of services to the industry, the incorporation of disruptive technology and medical-scientific excellence, and directed towards systems intelligent IT and data exploitation (IA/BIG DATA). Molecular companion diagnostics tests provide essential information that enables doctors to identify those patients that are most likely to benefit from a treatment.

We believe that relentless research, bold initiatives, sustained commitment and an unapologetic determination to succeed against cancer will help us defeat it. We dedicate ourselves to this singular mission as if our life depends on it. Cancer is a leading cause of death globally. Datar Cancer Genetics is a leader in developing blood-based diagnostics that can detect cancer early, offer non-invasive investigations for better treatment options, and track the progression of the disease or its recurrence. We believe that relentless research, bold initiatives, sustained commitment, and an unapologetic determination to succeed against cancer will help us defeat it. At the forefront of this revolution are our visionary scientists, who have devoted their expertise and ingenuity to craft unparalleled customized, non-invasive tests for the benefit of patients. Our groundbreaking tests serve as the key to unlocking the potential of molecularly targeted therapies, providing a profound understanding of tumor heterogeneity and dynamic tumor biology.

We are driven forward by a vision of a future where cancer is curable. We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are applying our multi-omics, computational biology and machine learning approach to capture cancer’s signal for high-burden gastrointestinal cancers. Starting with colorectal cancer, we are building a multi-cancer platform that can identify the unique DNA regions associated with different types of cancers. Cancer’s early detection has become one of the greatest challenges of modern medicine, so we decided to team up with the best. Our company was founded on Silicon Valley’s ideals of technology and development (Singularity University), and we developed a network of world-class R&D partners including Quest Diagnostics and Hologic (Diagenode). Our Scientific Advisory Board includes leading oncologists, gastroenterologists and business experts from the US and Europe. We have built a network of >100 hospitals in the U.S.

We are experts in developing and providing personalised cancer genetics tests for doctors and patients, and testing tumours for sensitivity and resistance to chemotherapy treatment and a range of natural substances. We encourage imaginative thinking to explore, question and reinvent, creating products, systems and technologies to challenge expectations. Working in the field of advanced medical genetics, our team of scientists and medical experts have developed a range of reliable tests so patients and clinicians can make informed decisions about healthcare. This is why we’re focused on creating modern and innovative products that will have a positive impact on day-to-day living.